- Home
- PDX vs RIGL Comparison
PDX vs RIGL Comparison
Compare PDX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDX | RIGL |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 931.2M | 911.8M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PDX | RIGL |
|---|---|---|
| Price | $20.17 | $47.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $63.00 |
| AVG Volume (30 Days) | 122.4K | ★ 217.9K |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | N/A | $21.95 |
| P/E Ratio | ★ N/A | $35.47 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $18.47 | $24.84 |
| 52 Week High | $22.59 | $52.24 |
Technical Indicators
Market Signals| Indicator | PDX | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 51.18 |
| Support Level | $19.98 | $44.50 |
| Resistance Level | $20.36 | $49.50 |
| Average True Range (ATR) | 0.30 | 1.88 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 32.61 | 42.51 |
Price Performance
Historical ComparisonAbout PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.